SRRA stock: buy or sell?
January 17th, 2020
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.
Should I buy SRRA stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Sierra Oncology stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Sierra Oncology stock a buy?
Financial institutions and banks post stock ratings everyday.Unfortunately, we couldn't find any rating for SRRA stock for the last month.
SRRA stock analysis
Sierra Oncology plummed a dreadful -4.76% and closed at $0.40.
Shares of Sierra Oncology plummed a dreadful -4.76% and closed at $0.40. From a daily perspective, SRRA is in a short term uptrend after plotting its last bottom ($0.35, on Jan/6) higher than the previous bottom, and its last top ($0.49, on Monday) also over the previous top. Now trading in between its last bottom and last top SRRA might consolidate in a plain range, waiting to break out over $0.49 or down under $0.35. Since price and SMA100d lines crossed up on January/9, SRRA climbed $0.04 (11.11%).
After sliding a dreadful -5.26% in a week last week, Sierra Oncology closed this week at $0.40 and climbed a great 5.26%.
Sierra Oncology stock just marked a top under its last top. Athought it's not a big concern right now, investors in SRRA should be aware as this could be a warning for future complications. You should be expectant to Sierra Oncology price to not slide under , as this would complicate possible price recovery in the short and mid-term. Since late March 2019, when SRRA stock price broke down the 40-weeks moving avarage line, it slid $-1.47 per share (-78.61%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.
SRRA stock price history
SRRA stock went public on July 16th, 2015 with a price of $28.681. Since then, SRRA stock sliced a -98.60%, with a yearly average of -24.70%.
1: Adjusted price after possible price splits or reverse-splits.
SRRA stock historical price chart
SRRA stock reached 52-week highs on March at $2.01, and all-time highs 2015-07-16 with a price of 33.75.
SRRA stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' SRRA stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price prediction for Sierra Oncology stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSierra Oncology let down experts on February when it posted an Earnings per Share (EPS) of $-0.19 when the analysts' forecast was $-0.21.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Sierra Oncology annual revenues to million dollars from marked in . , its earnings margin (compared to revenues) to , that is million.
Quarterly financial resultsReported quarter income marked $-14.28 million with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Sierra Oncology sales marked a tight movement and stayed constant a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 positive quarters in a row.
Sierra Oncology ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Sierra Oncology, 1.07% of all outstanding shares are owned by its staff.
In case of Sierra Oncology stock, 51.89% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$29.9 M||$97.6 M||$182.0 M|
|Total shares||74.7 M||11.6 M||55.0 M|
|Float shares||60.6 M||4.9 M||41.5 M|
|- Institutional holdings (%)||51.9%||50.6%||63.3%|
|- Insider holdings (%)||1.1%||21.2%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, January 17th, 2020|
|Day range||$0.40 - $0.43|
|Average true range||$0.05|
|50d mov avg||$0.35|
|100d mov avg||$0.36|
|200d mov avg||$0.64|
Sierra Oncology performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Sierra Oncology, the comparison is made against Champions Oncology and Pieris Pharmaceuticals.